AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05629650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi for memory
Description: The adapted form of TCM will be provided at 60 minutes per session, twice a week for 12 weeks by a certified Tai Chi instructor who had experience in teaching older adults with cognitive impairments.
Study NCT02153372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMC2012
Study NCT02864381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: 800 mg administered via IV infusion
Study NCT02864381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg administered via IV infusion
Study NCT02864381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 3 mg/kg administered via IV infusion
Study NCT01903018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00
Study NCT01903018 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT01903018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02120625 — intervention group
Intervention type: DEVICE
Intervention: Lumbar MB RFN
Description: Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
Study NCT04544345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: His bundle pacing, AV optimized
Description: A Select Secure 3830 (Medtronic, MN, USA) pacing lead will be placed on the bundle of His. In case of unsuccessful His capture, left bundle branch area pacing is going to be targeted. Pacemaker will be programmed to a low base rate and a high tracking rate to allow for intrinsic sinus rhythm. AV delay will be optimized with echocardiography to the shortest AV delay without truncation of the A wave on transmitral pulse wave doppler.
Study NCT04544345 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Backup VVI pacing
Description: Pacemaker will be programmed to VVI (ventricular only) mode with low base rate as to allow for intrinsic sinus rhythm without AV optimization.
Study NCT04010513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Women in the hypnosis group will undergo treatment with three in-person hypnosis sessions and will be given access to hypnosis web-app for at home practice.
Study NCT04010513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Women in the usual care group will continue their usual care for BPS/IC as dictated by their physicians.
Study NCT00234494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m2, day 1
Study NCT00234494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m2, day 1 and 8
Study NCT00234494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15mg/kg, day 1
Study NCT03205215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
Study NCT03205215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waitlist Hyperbaric Oxygen Therapy
Description: 100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
Study NCT01409863 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: laser and standard diamond fraise dermabrasion
Description: standard dermabrasion, CO2 laser resurfacing
Study NCT00667355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg or 80 mg every other week, subcutaneous
Study NCT00616434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG9418 (Interferon beta-1a)
Description: Avonex IM injection, self-administered per protocol
Study NCT00616434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IM injection, self-administered per protocol.
Study NCT02212873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyBFF@school program
Description: Students will be required to participate in all 3 components of MyBFF@school (SSG, nutrition and psychology sessions) for 16 weeks under the supervision of trained researchers, then for another 16 weeks supervised by their respective teachers-in-charge of physical education and/or co-curriculum activity. Each SSG session will be for an hour, thrice weekly while the nutrition or psychology session will be for 30-45 minutes once a week.
Study NCT04471948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional picosecond 1064 nm laser
Description: The parameter of laser was 8 mm spot size, 0.8 mJ/CM2, 750 ps, 5 Hz, 2 passes The treatment was done in every 4 weeks for 3 sessions.
Study NCT04279262 — intervention group
Intervention type: OTHER
Intervention: attendance by community first responders for medical emergencies
Description: The investigators will purposively sample patients, relatives, and ambulance staff identified from records of patients who have been attended by a CFR in a rural location in the previous six months. Where possible the investigators will interview patients, relatives, CFRs and ambulance staff attending the same event. GPs will be purposively sampled from rural areas of the ambulance services involved. Investigators will recruit a maximum variation sample of patients (according to age, sex, condition, and ethnicity), ambulance staff (sex, experience, ethnicity and role), CFR (sex, ethnicity, length of experience, skill level) and CFR scheme leads (independent charity and ambulance trust overseen schemes).
Study NCT02287311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MABEL CTLs
Description: Dose escalation:~DL1:2x10\^7 cells/m2+2x10\^7 cells/m2~DL2:2x10\^7cells/m2+5x10\^7 cells/m2~DL3:5x10\^7 cells/m2+1x10\^8 cells/m2~\*Doses are based on total CD3+cells/m2~Patients with active disease that have apparent clinical benefit at the 8 wk post 1st infusion (6 wks after 2nd infusion) or subsequent evaluations may receive up to 6 additional doses of CTLs at intervals at least 6 wks apart, each of which will consist of the same cell number as their second injection or below the original dose if there is not enough product available for the original dose. Patients may receive lymphodepleting chemotherapy (Cy/Flu) before additional infusions. Patients cannot receive additional doses until the initial safety profile is completed at 6 wks following the second infusion.
Study NCT02287311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion.
Study NCT02287311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide and fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion.
Study NCT00347672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
Description: Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)
Study NCT04012437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sphincter Control Training (SCT)
Description: The SCT + device consists of 8 different exercises and an educational session into a app using a masturbation electronic aid device
Study NCT04012437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sphincter Control Training (SCT)
Description: The SCT consists of 4 different exercises and an educational session into a app using a masturbation electronic aid device
Study NCT01753154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solution B (balance PD solution)
Description: balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium
Study NCT01753154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solution A (conventional PD solution)
Description: Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
Study NCT01612741 — intervention group
Intervention type: DRUG
Intervention: Acarbose (Precose/Glucobay, BAYG5421)
Description: Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
Study NCT00556153 — intervention group
Intervention type: DRUG
Intervention: [F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical
Description: A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
Study NCT01681134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf®
Description: oral
Study NCT01681134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf®
Description: oral
Study NCT04356248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Training
Description: Treatment in both arms consists of specific endurance exercise modalities (HIIT or ST). Treatments differ in the applied training intensities. Participants in both arms will exercise 3 times per week over a period of 3 weeks on a bicycle ergometer. Exercise sessions will be supervised by a trained physical therapist. Exercise intensity will be heart rate monitored based on the maximum heart rate (HRmax) assessed during the initial cardiopulmonary exercise test. Exercise sessions in both arms will include a warm-up and a cool-down period at low intensity (50% HRmax) for 3 min each.
Study NCT04356248 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training
Description: Treatment in both arms consists of specific endurance exercise modalities (HIIT or ST). Treatments differ in the applied training intensities. Participants in both arms will exercise 3 times per week over a period of 3 weeks on a bicycle ergometer. Exercise sessions will be supervised by a trained physical therapist. Exercise intensity will be heart rate monitored based on the maximum heart rate (HRmax) assessed during the initial cardiopulmonary exercise test. Exercise sessions in both arms will include a warm-up and a cool-down period at low intensity (50% HRmax) for 3 min each.
Study NCT04356248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Treatment in both arms consists of specific energy management education interventions (IEME or PMR). Treatments differ in the applied education approaches. Participants in both arms will exercise 2 times per week over a period of 3 weeks.
Study NCT04356248 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Treatment in both arms consists of specific energy management education interventions (IEME or PMR). Treatments differ in the applied education approaches. Participants in both arms will exercise 2 times per week over a period of 3 weeks.
Study NCT01679366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet 2 times daily
Study NCT01679366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 1 tablet twice daily
Study NCT05104008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lateral wedge insoles with home exercises group(Group 1)
Description: In this group, participants were advised to use lateral wedge insole during walking and long-standing. Non customized full-length lateral wedge insoles of 7mm made of silicon material with 5 degrees angulation (because greater wedging is associated with foot discomfort) was used. Full-length wedge extends under the lesser metatarsal heads which increases the lever arm for rearfoot eversion and thus can prevent subtalar joint rotation. The evaluations were performed every week till fourth week.
Study NCT05104008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy with home exercises group (Group 2)
Description: Each participant received 40-45 minutes long session, started in lying position. The therapeutic low-intensity pulsed ultrasound (US) was used for 7 minutes with the frequency of 1 MHz, Spatial Average Intensity was 0.2 W /cm2, pulsed duty cycle 20%, therapeutic dose was 112.5 J/cm2 with fixed application on the medial side of the knee joint. The model of US was Unit Intelect Mobile, (Chattanooga Inc). After US therapy passive stretching of calf, hamstring, quadriceps, hip flexors, adductors \& abductor s was done, which was followed by the manual strengthening exercises and strengthening with quadriceps bench. The session was repeated thrice a week and 12 sessions per month. The home program was guided in both groups including avoiding low sitting, cross leg sitting along with Isometrics of quadriceps atleast 3 times a day, with 5-10 seconds hold of each contraction.
Study NCT01777087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gauze soaked with capsaicin
Description: This is a basic science study determining the brain activation that results from painful stimulation. All subjects will have the same painful stimulations and brain images collected.
Study NCT04571827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Deep dry needling procedure~All subjects received a deep dry neddling technique on a latent myofascial trigger point of the upper trapezius muscle by isolating it by a pincer grasp with the thumb and index finger. This myofascial trigger point was previously found following the diagnostic criteria described by Travell \& Simons and Fernández-de-las-Peñas et al., and the deep dry needling intervention applied was based on the technique described by Hong.~The patients were placed in a prone position. Prior to the technique, the area was disinfected with an antiseptic solution. Fifteen incisions were made with a 0.26x40mm monofilament needle. The number of local twitch response made were noted. After removing the needle, at the end a soft compression was made with a cotton to reduce the possible appearance of bleeding.
Study NCT03819010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib
Description: Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 18-25
Study NCT03819010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib
Description: Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 26-100
Study NCT03504514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: speech trials during different ventilation conditions
Description: ventilator parameters are modified
Study NCT03504514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speech trial
Description: reading duration, vocal flow, intelligibility and voice quality will be evaluated during speech
Study NCT02749422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MagStim RapidStim2
Description: Repetitive transcranial magnetic stimulation (TMS)
Study NCT02749422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MagStim RapidStim2
Description: Repetitive transcranial magnetic stimulation (TMS)
Study NCT00701207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: daily transdermal patch 7 mg, 14mg, 21 mg. 3 months
Study NCT00538304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost eye drops
Description: 1 drop in each eye daily for 1 month
Study NCT00538304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 drop in each eye daily for 1 month
Study NCT01817855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7624
Description: Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer
Study NCT01817855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match
Description: Multiple doses inhaled placebo via a nebulizer
Study NCT00992511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: One intramuscular injection of initial process-manufactured GSK2340272A vaccine
Study NCT00992511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Two intramuscular injections of initial process-manufactured GSK2340272A vaccine
Study NCT00992511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: One intramuscular injection of new process-manufactured GSK2340272A vaccine
Study NCT00992511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Two intramuscular injections of new process-manufactured GSK2340272A vaccine
Study NCT04276922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Arts
Description: Subjects meet for 90 minutes, once weekly, over 12 weeks for guided drawing/sketching sessions. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation.
Study NCT04276922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Subjects meet for 90 minutes, once weekly, over 12 weeks, for guided music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making. The 12 sessions follow a standard sequence, addressing three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards are completed at baseline, weekly and at completion to assess satisfaction, stress, and well-being. Qualitative focus groups, after the intervention, assess acceptability of intervention, outcomes, program development and implementation.
Study NCT04276922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance/Movement
Description: Subjects will meet once weekly, and begin with a movement check-in, a gentle physical warm-up, and then either a structured or improvisational movement process. for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation.
Study NCT04276922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing/Poetry
Description: Subjects will meet once weekly, for writing workshops to encourage participants to tell the stories they need to tell, using integral elements of good writing, for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation.
Study NCT04276922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control Group will only complete surveys at baseline and 12 weeks later.
Study NCT03260595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2%
Description: Crisaborole ointment 2%
Study NCT03260595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle